Ray Dalio's ATRC Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 33,517 shares of AtriCure, Inc. (ATRC) worth $956,240, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 16 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in ATRC, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 33,517 shares. Largest reduction occurred in Q3 2023, reducing 38,723 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's AtriCure (ATRC) Holding Value Over Time
Track share changes against reported price movement
Quarterly AtriCure (ATRC) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +33,517 | New Buy | 33,517 | $28.53 |
| Q4 2024 | -19,685 | Sold Out | 0 | $0.00 |
| Q3 2024 | -20,632 | Reduce 51.17% | 19,685 | $28.04 |
| Q2 2024 | -5,692 | Reduce 12.37% | 40,317 | $22.77 |
| Q1 2024 | +25,579 | Add 125.20% | 46,009 | $30.42 |
| Q4 2023 | -1,517 | Reduce 6.91% | 20,430 | $35.69 |
| Q3 2023 | -38,723 | Reduce 63.83% | 21,947 | $43.80 |
| Q2 2023 | -4,676 | Reduce 7.16% | 60,670 | $49.36 |
| Q1 2023 | +11,732 | Add 21.88% | 65,346 | $41.45 |
| Q4 2022 | -18,248 | Reduce 25.39% | 53,614 | $44.38 |
| Q3 2022 | +93 | Add 0.13% | 71,862 | $39.10 |
| Q2 2022 | +6,983 | Add 10.78% | 71,769 | $40.85 |
| Q1 2022 | +15,930 | Add 32.61% | 64,786 | $65.66 |
| Q4 2021 | +6,926 | Add 16.52% | 48,856 | $69.53 |
| Q3 2021 | -1,494 | Reduce 3.44% | 41,930 | $69.54 |
| Q2 2021 | +43,424 | New Buy | 43,424 | $79.33 |
Ray Dalio's AtriCure Investment FAQs
Ray Dalio first purchased AtriCure, Inc. (ATRC) in Q2 2021, acquiring 43,424 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held AtriCure, Inc. (ATRC) for 16 quarters since Q2 2021.
Ray Dalio's largest addition to AtriCure, Inc. (ATRC) was in Q2 2021, adding 43,424 shares worth $3.44 M.
According to the latest 13F filing for Q1 2026, Ray Dalio's firm, Bridgewater Associates, Lp, owns 33,517 shares of AtriCure, Inc. (ATRC), valued at approximately $956,240.
As of the Q1 2026 filing, AtriCure, Inc. (ATRC) represents approximately 0.00% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in AtriCure, Inc. (ATRC) was 71,862 shares, as reported at the end of Q3 2022.